Top Tech Companies (113)
Don't see your company?
Create a company profile
CHAIN Biotechnology was founded in 2014, by serial entrepreneur Dr Edward Green, to exploit the therapeutic potential of Clostridia bacteria found in the human gut microbiome. CHAIN has built an impressive technical team of molecular biology, microbiology, microbiome and fermentation specialists focused on the biotechnology development of Clostridia. In addition, CHAIN leverages synthetic biology expertise from the Synthetic Biology Research Centre at the University of Nottingham. CHAIN has developed a proprietary microbial platform for drug delivery. The platform builds on core engineering skills and involves the development and use of engineered Clostridia to deliver specific therapeutics to the gut. CHAIN’s Clostridium Assisted Drug Delivery (CADD™) delivery platform is highly differentiated and supports a therapeutic product pipeline for a wide range of clinical indications including localised infection, inflammation and CNS signalling. Our lead asset is an engineered strain that secretes a novel and potent anti-inflammatory molecule targeting Inflammatory Bowel Disease, a chronic gut disease affecting millions worldwide.
Genz is a spin-off biotech company developing novel solutions from in vitro diagnostics to therapeutics. Our mission is to deliver a consistent stream of innovative, affordable, and accessible diagnostic solutions and make a remarkable impact on people’s lives. We’re focused on sustainable growth and addressing the world’s pressing health challenges; therefore, we’re able to create value for both our patients and our shareholders. To date, Genz developed 4 IVD diagnostic tests commercially legalized, attended International joint projects, partnered with top research centers in the world and published several scientific articles in international scientific journal
Resolution Therapeutics is a biotechnology company developing macrophage cell therapy to treat inflammatory organ disease. The company was founded following a productive collaboration between Edinburgh’s Centre for Regenerative Medicine, the Scottish National Blood Transfusion Service, and Syncona Investment Management Limited. The company is based in the Centre for Regenerative Medicine on the Edinburgh Royal Infirmary Campus, and is backed by Syncona. Our initial focus is in chronic liver disease. It is the only chronic disease still on the rise in western countries, and affects millions of people worldwide. Unfortunately, only supportive therapies are currently available. For patients with end-stage liver disease (cirrhosis) the only therapeutic option is liver transplantation, a complex surgical procedure limited by complications and a shortage of donors. At Resolution Therapeutics, we are developing a macrophage cell therapy product to treat patients at risk of liver decompensation, thus helping them avoid the need for a liver transplant.
Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects.
FabricNano is a biotechnology company based in London. Our mission is to transform industrial chemical processes using cell-free biomanufacturing. Empowering users with the world’s most advanced, flexible and easily-scalable biocatalyst platform. We develop and sell biocatalysts for high volume industrial applications. Data-driven in our approach to enzyme and Immobilization Engineering™, we only use biocatalyst materials that can already be manufactured by the tonne. Our clients range from startups to international chemical clients like Sumitomo Chemical Company, all of which are looking for highly stable and performant biocatalysts to enable profitable production of sustainable and bio-based chemicals. The FabricNano offer starts with novel Immobilization Engineering™ for enzyme stabilization, followed by budget-conscious protein engineering and process engineering to reach the client’s targets for commercialization of the new biochemical production process.
Pulmocide is a biopharmaceutical company that specializes in tackling difficult-to-treat respiratory diseases. We focus on respiratory fungal infections that can be serious and life-threatening and have significant effects on patients’ quality of life. Our current clinical development focus is on treating patients who have not successfully responded to the standard of care and on the prophylactic treatment of lung transplant patients. Pulmocide’s innovative approach to drug development provides a novel potential therapy that has been specifically designed to treat the most common fungal lung disease, pulmonary aspergillosis. Opelconazole was designed for inhaled delivery to minimize systemic exposure and deliver a high concentration of drug with a long retention time at the site of infection. This approach could improve treatment outcomes in patients with fungal lung disease without increasing systemic side effects and without interactions with other medications. The Pulmocide team is well experienced in the discovery and development of inhaled therapies for respiratory and infectious disease indications. They have particular expertise in the identification of novel compounds that can be delivered directly to the lungs.
Modern Synthesis is a London based biomaterial company connecting the dots between biology, material science and design to craft the next generation of biomaterials for the fashion industry
Phytoform are making agriculture sustainable & unlocking the genetic potential of plants.
Ascend is an end-to-end gene therapy development partner with deep expertise in gene therapy development and commercialization. We offer unparalleled collaboration while working to develop your products from the bench through the clinic and beyond. Scientific innovation driven by quality and responsibility are at the core of our business. To set a new standard in the industry, we have invested in a world-class analytical toolkit within our flexible and scalable AAV platform of next-gen technologies, all built to find the perfect balance of yield and quality for each process. Let’s aim higher and develop the next wave of accessible life-saving therapies together!
Causaly amplifies human cognitive abilities to expand the boundaries of discovery towards making the best decisions in Biomedicine. To achieve this, we are teaching computers to read all knowledge ever published and develop an interface that allows humans to answer questions they can’t ask anywhere else.
Inoviv uses a novel technology platform based on targeted proteomics to support pharmaceutical companies with biomarker test development.
An exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions. Our company is growing and we are exciting about the future! Our vision is to become a world leader in new cell therapy and the people are at the heart of what we do. We treat our people with respect, working collaboratively across the business, taking ownership and accountability for the outcomes and results we delivery. Most of all we work with integrity to innovate and bring the best version of ourselves to the job every day.
Let's transform lives together and work towards a functional, confident smile on every face
Enara Bio is shining a light on Dark Antigen® and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients. Our pioneering EDAPT® platform enables us to discover novel cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing database of Dark Antigens that can address the unmet need for cancer-specific targets that are homogenously expressed and highly prevalent in solid tumors. We are advancing multiple approaches to exploit these Dark Antigen targets, with an internal focus on TCR-directed immunotherapies, and additional therapeutic partnerships with Boehringer Ingelheim and another undisclosed global pharmaceutical company. Based in Oxford, UK, Enara Bio is backed by RA Capital, Samsara Biocapital and SV Health Investors. For more information, please visit: www.enarabio.com Comments and DMs to this account are not monitored, for any further information please head to our website
ENBIOSIS Biosciences reaches deep into your inner world with microbiome analysis and offers you the key for a sustainable and healthy life
Atlas Biomed is a personalized health company applying the latest genetic technologies to inspire consumers into a positive lifestyle change, and lead them into a healthier future.
Baseimmune was founded in 2019 as a discovery phase start-up in the antigen discovery and vaccine development field
We believe that everyone - irrespective of who they are or where they live - deserve medications that work
LoQus23 are discovering oral small molecule therapies targeting aberrant DNA mismatch repair to effectively treat Huntington’s and other triplet repeat diseases
Detecting brain diseases radically early using the way you speak
